February 12, 2018 / 12:53 PM / 3 months ago

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

Feb 12 (Reuters) - Amicus Therapeutics Inc:

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

* AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below